# A Study to Evaluate the Efficacy and Safety of Dual add-on Therapy With Gemigliptin 50 mg and Dapagliflozin 10 mg Added to Metformin Who Have Inadequate Glycemic Control on Metformin Alone

> **NCT04255238** · PHASE3 · UNKNOWN · sponsor: **LG Chem** · enrollment: 468 (estimated)

## Conditions studied

- Diabetes Mellitus, Type 2

## Interventions

- **DRUG:** Gemigliptin 50mg
- **DRUG:** Dapagliflozin 10mg

## Key facts

- **NCT ID:** NCT04255238
- **Lead sponsor:** LG Chem
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2020-06-30
- **Primary completion:** 2022-05-30
- **Final completion:** 2022-12-30
- **Target enrollment:** 468 (ESTIMATED)
- **Last updated:** 2020-02-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04255238

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04255238, "A Study to Evaluate the Efficacy and Safety of Dual add-on Therapy With Gemigliptin 50 mg and Dapagliflozin 10 mg Added to Metformin Who Have Inadequate Glycemic Control on Metformin Alone". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT04255238. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*